Adiponectin-Induced Antitumor Activity on Prostatic Cancers through Inhibiting Proliferation

Cell Biochemistry and Biophysics

Volumn 70, Issue 1, 2014, Pages 461-465

  Gao, Qiruo ^a   Zheng, Junhua ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Adiponectin; Obesity; Prostate cancer

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPOR1 PROTEIN, HUMAN; ADIPOR2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADIPONECTIN; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ADIPONECTIN;

EID: 84906252380     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9941-4     Document Type: Article

References (16)

1. Calle, E. E., et al. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. New England Journal of Medicine, 348(17), 1625-1638.
2. Heliovaara, M. K., et al. (2006). Association of serum adiponectin concentration to lipid and glucose metabolism in healthy humans. Hormone and Metabolic Research, 38(5), 336-340.
3. Michalakis, K., et al. (2007). Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: A case control study. Cancer Epidemiology, Biomarkers and Prevention, 16(2), 308-313.
4. Mistry, T., et al. (2008). Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU International, 101(10), 1317-1322.
5. Barb, D., et al. (2007). Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. American Journal of Clinical Nutrition, 86(3), s858-s866.
6. Kelesidis, I., Kelesidis, T., & Mantzoros, C. S. (2006). Adiponectin and cancer: A systematic review. British Journal of Cancer, 94(9), 1221-1225.
7. Perrier, S., & Jarde, T. (2012). Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Current Medicinal Chemistry, 19(32), 5501-5512.
8. Yoneda, K., et al. (2008). Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncology Reports, 20(3), 479-483.
9. Ishikawa, M., et al. (2005). Plasma adiponectin and gastric cancer. Clinical Cancer Research, 11(2 Pt 1), 466-472.
10. Yamamoto, H., et al. (2013). Association between reduction of plasma adiponectin levels and risk of bacterial infection after gastric cancer surgery. PLoS One, 8(3), e56129.
11. Nakajima, T. E., et al. (2010). Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Science, 101(5), 1286-1291.
12. Tewari, R., et al. (2013). Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men: A cross-sectional study. Cytokine, 63(2), 130-134.
13. Gross, A. L., et al. (2013). Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: A prospective study. Cancer Epidemiology, Biomarkers and Prevention, 22(7), 1319-1324.
14. Yamauchi, T., et al. (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423(6941), 762-769.
15. Yokota, T., et al. (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96(5), 1723-1732.
16. Brakenhielm, E., et al. (2004). Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 101(8), 2476-2481.